New Delhi: There is no scientific evidence so far to support the need for a booster vaccine dose against Covid-19, Director General of ICMR Dr.
Balra Bhargava said on Monday that underlines the second dose completion for the Indian adult population is a priority for the government now.
According to sources, the problem of the booster dose is likely to be discussed at the next meeting of the National Technical Advisory Group on immunization in India (Ntagi).
“Converlating the second dose of Covid-19 vaccines for all adult populations and ensuring that not only India but the whole world will vaccinate the government’s priority for now.” Moreover, there is no scientific evidence so far to support the need for a dose of booster vaccine against Covid-19, “said Bhargava to PTI.
In the probability of granting a dose of booster, Health Minister Mansukh Mandaviya recently said that adequate stocks were available and The aim is to resolve the target population vaccination with two doses.
After that, the decision on the booster dose will be taken based on the expert recommendation, he said.
“The government cannot make direct decisions in such problems.
When the Indian Medical Research Board and the expert team will say that the booster dose must be given, we will consider it later, “he said, adding that Prime Minister Narendra Modi always depends on expert opinion, whether it’s a vaccine research, manufacturing or approval.
According to officials, around 82 percent of eligible populations in India have received the first dose of vaccines while around 43 percent have fully invested.
The total number of covid-19 vaccine doses provided in this country have exceeded 116.87 crores, according to a temporary report until 7 in the morning.
The government has launched a campaign ‘Har Ghar Dastak’ all months for covid-19 house vaccination from those who have not taken a dose and for the second dose of people.
It’s past.
According to officials, more than 12 crore recipients are late for the second dose of the covid vaccine- 19 They after the end of the interval determined between two doses.